V01AA05 - Tree Pollen |
Propably not porphyrinogenic |
PNP |
Rationale
Tree pollen extracts consists mainly of polypeptides and proteins that are not subject to liver metabolism or interaction with CYP enzymes.
Therapeutic characteristics
Allergen extracts containing tree pollen are used in allergy immunotherapy, to desensitize people that have an allergy to tree pollen. It is administered as a subcutaneous injection. It may be used continuously throughout the season or for up to 3to 5 years for long term efficacy (SPC).
Metabolism and pharmakokinetics
The allergen is presumably taken up by dendritic cells and presented to other cells of the immune system.
It is not expected that the allergens is absorbed into the vascular system to any significant extent.
No pharmacokinetic studies in animals or clinical studies have been conducted (EMEA, Pfaar 2014, SPC).
References
- Scientific articles
- Pfaar O, Bachert C, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int. 2014; 23(8): 282–319. PMID 26120539. #4726
- Government bodies
- EMEA. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP): Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases; EMEA/CHMP/EWP/18504/ 2006. 2008. #4797
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Alutard. #2951
Similar drugs
© NAPOS 2024